Loading
A phase 3 trial of Ropeginterferon alfa-2b and Anagrelide in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance is a phase 3 interventional study registered as NCT04285086 by PharmaEssentia, with 174 participants enrolled, started 2020-08-25 and due to reach its primary completion in 2024-11-12. Interventions recorded: Ropeginterferon alfa-2b and Anagrelide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Essential thrombocythaemia (ET), Cytokines & engineered cytokines and the tag pipeline.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Essential thrombocythaemia (ET), Cytokines & engineered cytokines and the tag pipeline.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Essential thrombocythaemia (ET) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/